Immunotherapy for Hematologic Malignancies
Ce dossier présente un ensemble d'articles concernant la biologie et le traitement par immunothérapie de cancers hématologiques
Hematologic malignancies have always been at the forefront in the application of immunotherapy against cancer. The susceptibility of blood cancers to immunotherapy was first established in the 1970s by the demonstration that a potent and, crucially, manipulable immunologically mediated graft-versus-leukemia (GVL) effect played a major contribution to the curative potential of allogeneic stem cell transplantation (allo-SCT).1-4 In 1997, rituximab, the first anticancer monoclonal antibody, was approved for patients with relapsed indolent B-cell lymphoma.5 Over the past decade, the advent of a range of novel pharmacologic and cellular strategies with the capacity to deliver specific immunologic antitumor responses has transformed the management of hematologic malignancies. Articles in this Special Series examine these advances with a focus on clinical applications. Key themes include improving allo-SCT outcomes through increased donor availability and innovative transplant technology, novel cellular therapies including new chimeric antibody receptor T cell (CAR-T) constructs, the application of checkpoint inhibition, and other novel immunotherapeutic targets.